American College of Rheumatology recommends biosimilars for rheumatic disease

In a white paper published in Arthritis & Rheumatology, the American College of Rheumatology now recommends the use of biosimilars to treat rheumatic disease, saying they should be incorporated into the U.S. healthcare system.

The authors wrote that they reevaluated their position based on evidence from Europe, as "biosimilars have been used successfully in Europe, with rigorously acquired data supporting their broader use" and biosimilars gaining traction in the U.S. In 2015, the ACR released a position statement emphasizing that close monitoring of differences between biosimilars and their reference biologics should be examined as new drugs are developed...